Comparative evaluation of the performance of 18F-PSMA-1007 PET/CT and 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence.

AIM: In this study, we aimed to evaluate the diagnostic performance of 18F-PSMA-1007 PET/CT compared to 68Ga-PSMA-11 PET/CT, which is more commonly used in routine practice, for detecting prostate cancer recurrence in prostate cancer patients with biochemical recurrence.

MATERIALS AND

METHODS

Forty-one prostate cancer patients with biochemical recurrence were prospectively included in the study. Additionally, images from 46 patients in our institution's database, who had undergone 68Ga-PSMA-11 PET/CT imaging for biochemical recurrence, were retrospectively re-evaluated to compare the detection rates with those of 18F-PSMA-1007 PET/CT. SUVmax, total tumor PSMA, PSMA total tumor volume were calculated for local recurrence, lymph node metastasis, and organ metastasis. The diagnostic performances of the two imaging methods were then compared.

RESULTS

The mean age, Gleason scores, ISUP scores, serum PSA levels at diagnosis and at the time of imaging, and PSA doubling times were similar across the 18F-PSMA-1007 and 68Ga-PSMA-11 groups. Pathological uptake was observed in the prostatic bed in 16 patients (39.0%), lymph nodes in 22 patients (46.3%), and bones in 11 patients (26.8%) with 18F-PSMA-1007 PET/CT. 18F-PSMA-1007 PET/CT showed statistically significant superiority over 68Ga-PSMA-11 PET/CT in detecting lymph node metastases (41.6% vs. 25.4%; P=.028). There was no significant difference between the two imaging protocols in the detection rates of local recurrence (P=.067) and bone metastasis (P=.580).

CONCLUSION

Although the study included a small sample size, the results revealed that 18F-PSMA-1007 PET/CT had a higher detection rate than 68Ga-PSMA-11 PET/CT in patients with biochemically recurrent prostate carcinoma, particularly for lymph node metastases.